Vaccine effectiveness against SARS-CoV-2 infection wanes over time
Jun 14, 2022
However, for all ages, vaccine effectiveness against severe COVID-19 was high overall, at 90% five months or longer after two doses.
Low risk seen for second allergic reaction to mRNA COVID-19 vaccine
Feb 22, 2022
Of 1,366 patients with an immediate allergic reaction to the first dose, six developed a severe immediate allergic reaction after the second dose.
Early effectiveness assessed for fourth dose of BNT162b2 vaccine
Apr 21, 2022
The difference in absolute risk for three versus four doses was 180.1 and 68.8 cases per 100,000 for COVID-19-related hospitalization and severe COVID-19.
mRNA vaccines effectively prevent SARS-CoV-2 in adults in real-world setting
Jul 01, 2021
For those with SARS-CoV-2 infection, vaccinated participants had a lower mean viral load, risk of febrile symptoms and illness duration.
Fourth dose of BNT162b2 offers protection against severe COVID-19
Apr 08, 2022
Protection against COVID-19 did not wane in six weeks after receipt of fourth dose of the Pfizer–BioNTech vaccine; protection against the infection waned.
Fourth dose of BNT162b2 prevents severe COVID-19 in nursing home residents
Jun 27, 2022
Substantial protection against hospitalizations and deaths seen among nursing home residents during the omicron surge.
Risk for breakthrough SARS-CoV-2 infection lower with mRNA-1273
Feb 02, 2022
The risk for breakthrough infection and of 60-day hospitalization was significantly lower for mRNA-1273 (Moderna) versus BNT162b2 (Pfizer-BioNTech) vaccination.
Breakthrough SARS-CoV-2 infections ID’d in fully vaccinated
Aug 02, 2021
39 infections documented in 1,497 health care workers; 19 percent had persistent symptoms despite most cases being mild, asymptomatic
COVID-19 vaccine booster dose cuts infection in those 60 and older
Sep 17, 2021
A large Israeli study shows a reduction in confirmed infection and severe illness among adults 60 years of age and older.
Vaccination protects against death from SARS-CoV-2 delta variant
Oct 28, 2021
A Scotland cohort study shows that vaccination effectiveness with the ChAdOx1 nCoV-19 (Astra Zeneca, not available in the U.S.) or BNT162b2 (Pfizer–BioNTech) vaccine was 90% and 87%, respectively, for...